comparemela.com
  1. Home
  2. Live Updates
  3. Neurosense Therapeutics (NRSN) Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints : comparemela.com

Neurosense Therapeutics' (NRSN) Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints

Neurosense Therapeutics' (NRSN) Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Israel ,Italy ,Massachusetts ,United States ,Canada ,Ferenc Tracik ,Nasdaq ,Neurosense Therapeutics Ltd ,Company Phase ,Neurosense Therapeutics ,Slow Vital Capacity ,Massachusetts General Hospital ,Dorn Professor ,Harvard Medical School ,Scientific Advisory ,Ben Noon ,Chief Medical ,

© 2024 Vimarsana

comparemela.com © 2020. All Rights Reserved.